Israel-based life sciences, healthcare, and technology venture capital firm aMoon, together with an unnamed private investor, invested $5 million in cancer drug startup NanoGhosts, aMoon told Calcalist. This is NanoGhosts’s first investment.
Read More
Capital will enable continued advancement of novel Proteograph™ platform and commercialization of first-in-class proteomics products
Read More
The new entity, Vocalis Health, will develop technology for the voice-based analysis and detection of health issues such as heart and respiratory conditions and depression
Read More
The FDA, which approves all medical devices and formulations in the U.S., has very few branches outside of the U.S.
Read More
Based on technology developed by the Technion’s Prof. Yoram Reiter, Adicet Bio is developing allogeneic cell therapies for cancer using innovative gamma delta T cells.
Read More
aMoon Leads New Investment Round with Participation from OrbiMed and Lightspeed Venture Partners.
Read More
Tel Aviv – has “the highest number of startups per capita in the world…with more than 6,000, of which 18 are unicorns…more than 100 venture capital funds, plus hundreds of accelerators and co-working places.”
Read More
TEL AVIV (Reuters) – Israel’s Nobio Ltd said on Monday it received approval from the U.S. Food and Drug Administration to market its anti-bacterial composite designed to remain in the teeth for decades.
Read More
There’s fresh interest in a fabled shrub on the Aegean island of Chios.
Read More
Based in Jerusalem, Nasdaq-listed BiondVax develops a universal flu vaccine, currently in advanced clinical trials
Read More
With the closure of its sixth venture capital round, the Swiss health data firm Sophia Genetics added another $110 million to its coffers in a series F financing led by aMoon and Hitachi Ventures.
Read More
Not all olim arrive in Israel to serve in the IDF or go to university. In the case of two aMoon executives, coming to Israel was a way to advance their careers in venture capital health investments while also reaching the goal of living in the Jewish state.
Read More
Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the completion of its previously announced merger with resTORbio, Inc
Read More
Seer, Inc., an aMoon2 portfolio company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid and scalable proteomics information, today announced that it has spun out and completed the initial financing of $55M for a newly formed healthcare company, PrognomIQ, Inc.
Read More
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the completion of a £23 million ($30 million) Series A equity financing led by aMoon, Israel’s largest healthtech and life sciences venture fund.
Read More
aMoon leads round to expand product portfolio and advance commercial efforts for MOBILion’s SLIM technology for biotherapeutics characterization and novel biomarker discovery
Read More
has entered into a partnership agreement with aMoon, an Israeli venture capital company focused on health technology and science. The “StarFinder Lab” collaboration is aiming to help young startups develop innovative diagnostic tools to tackle global health care challenges.
Read More
Israel’s largest venture capital investor in life sciences, AMoon, boosted the size of its biggest fund to $750 million after demand for new health-care technology rose during the coronavirus pandemic.
Read More
Israel’s largest healthtech venture fund, aMoon, announced an investment of $6 million in Nectin Therapeutics Ltd. via its early-stage fund, aMoon Velocity.
Read More
Israel is fortifying its national survey of exposure to the coronavirus as a second wave of infections threatens to plunge the country back into lockdown.
Read More